Genetic variations in GABA metabolism and epilepsy
Yan Feng1, Zi-Han Wei2, Chao Liu2
1Xi'an Medical University, Xi'an 710021, People's Republic of China; Department of Neurology, Epilepsy Center of Xijing Hospital, Fourth Military Medical University, Xi'an 710032, People's Republic of China.
Seizure
|July 19, 2022
Summary
Genetic variations in gamma-aminobutyric acid (GABA) metabolism are linked to epilepsy. Understanding these genetic links aids in diagnosing and treating epilepsy and associated developmental disorders.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Epilepsy arises from an imbalance in neuronal excitation and inhibition.
- Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter, crucial for regulating brain activity.
- Dysregulation in GABA metabolism is implicated in epilepsy development.
Purpose of the Study:
- To review the relationship between genetic variations in GABA metabolism and epilepsy.
- To highlight advances in understanding these genetic links for improved diagnosis and treatment.
Main Methods:
- Review of scientific literature on GABA metabolism and epilepsy genetics.
- Analysis of gene mutations affecting GABA receptors and metabolic enzymes.
- Correlation of genetic variations with epilepsy syndromes and developmental disorders.
Main Results:
- Mutations in GABA receptor genes (e.g., GABRA1, GABRG2) alter receptor function and expression, contributing to epilepsy.
- Defects in GABA metabolic enzymes (encoded by ABAT and ALDH5A1) lead to epilepsy and cognitive impairment.
- Genetic variations in GABA metabolism are frequently associated with developmental disorders.
Conclusions:
- Genetic variations significantly impact GABAergic system function, leading to epilepsy.
- Understanding these genetic underpinnings is essential for targeted epilepsy diagnosis and therapy.
- Further research into GABA metabolism genetics can inform treatment strategies for epilepsy and related conditions.
More Related Videos
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
17.5K
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.1K
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
598
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
598
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
428
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
428
01:14Antiepileptic Drugs: Glutamate Antagonists
501
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
501
01:24Epilepsy and Seizures: Overview
271
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
271
01:20Antiepileptic Drugs: Potassium Channel Activators
269
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
269
01:20Inborn Errors of Metabolism
235
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
235